AwardJun 30, 2026, 04:07 PM
Aptevo Secures $1.5M Grant for APVO451 IND-Enabling Studies
AI Summary
Aptevo Therapeutics Inc. secured a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund. This funding will support Investigational New Drug (IND)-enabling studies for APVO451, the company's trispecific antibody candidate for solid tumor indications. The project period is expected to extend through June 2028, with funding provided on a reimbursement basis and subject to milestone achievement.
Key Highlights
- Aptevo received a $1,499,951.00 non-dilutive research grant.
- Funding is from the Andy Hill Cancer Research Endowment (CARE) Fund.
- Grant supports IND-enabling studies for APVO451, a trispecific antibody candidate.
- APVO451 targets solid tumor indications, leveraging nectin-4, CD40, and CD3 engagement.
- The project period is expected to extend through June 2028.
- Funding is on a reimbursement basis, subject to milestones and matching contributions.
- Company aims for APVO451 development candidate selection by year-end 2026.
- IND-enabling studies for APVO451 are planned for Q1 2027.
Price Impact
More from APVO
PartnershipMay 27, 4:12 PM
Aptevo, Niowave Form 50/50 Radiopharmaceutical Collaboration; Niowave Invests $500K
Quarterly ResultMay 13, 4:22 PM
Aptevo Therapeutics Raises Going Concern Doubt; Q1 Net Loss $(6.7)M
Business UpdateMay 13, 4:12 PM
Aptevo Reports Strong Mipletamig Data; Secures $60M Equity Line